

**Amendments to the Specification:**

After the title, please insert the following paragraph on page 1 of the specification:

**CROSS-REFERENCE TO RELATED APPLICATION**

The present application is a continuation of U.S. Patent Application Serial No. 09/779,928 filed on February 8, 2001, which claims the benefit of U.S. Provisional Application No. 60/182,635 filed on February 15, 2000.

Please substitute the following paragraph for the paragraph beginning on page 1, line 20 of the application.

Pyrimidine biosynthesis is a series of enzymatically catalyzed processes that convert carbamoyl phosphate and aspartic acid into cytidine triphosphate. About midway along the pathway lies the conversion of dihydroorotic acid to orotic acid by the dehydroorotate dehydrogenase enzyme. ~~Leflunomide~~ Leflunomide, N-(4'-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide (I), disrupts pyrimidine biosynthesis by inhibiting this enzyme.

Please substitute the following paragraph for the paragraph beginning on page 10, line 4 of the application.

The resulting leflunomide may be used directly or after further purification in pharmaceutical compositions and dosage forms as described, for instance, in commonly-assigned ~~co-pending application Serial No. Attorney docket No. 1662/50702~~ U.S. Patent No. 6,610,718, which is herein incorporated by reference in its entirety.